The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements.

 
Web www.patentalert.com

< Controlled Drug-Release Composition and Drug-Releasable Medical Device

> Glucagon Receptor Antagonists, Preparation and Therapeutic Uses

~ 00486